Broadly, there are two primary categories of EGFR family inhibitors: 1) Monoclonal antibodies that bind to the extracellular portion of the receptor,[110] Cetuximab and Panitumumab are FDA‐approved antibodies used as part of standard of care in certain cancer treatment[111]; and 2) Small molecule inhibitors that target the intracellular tyrosine kinase domain,[112] four generations of EGFR TKIs have been approved during last 2 decades. Here, EGFR is linked to cancer.